Abstract 81P
Background
mFOLFOX6 concurrent radiotherapy in the FOWARC study led to 27% of pCR rate in locally advanced rectal cancer (LARC). The total neoadjuvant treatment study (CAO/ARO/AIO-12) had compared the efficacy of chemoradiotherapy plus induction or consolidation chemotherapy. The result showed that consolidation chemotherapy led to higher pCR rate than that of induction chemotherapy. Here, we aimed to compare the efficacy of preoperative concurrent mFOLFOX6 chemoradiotherapy versus concurrent and consolidation chemotherapy during radiation as neoadjuvant treatment in locally advanced rectal cancer.
Methods
Prospectively maintained databases of patients from two clinical trials ( NCT01211210 and NCT02217020) underwent preoperative treatment for locally advanced rectal cancer were included. 143 patients received concurrent mFOLFOX6 chemoradiotherapy and TME surgery. 123 patients received concurrent and consolidation chemotherapy during radiation before TME. A comparative analysis was performed after the implementation of propensity score matching on the 2 main cohorts.
Results
A total of 266 patients were enrolled in the study. After propensity score matching, 180 patients were selected. 113 patients were comparable in the two groups. The pathologic complete response rate was comparable between the two groups (27.1% vs. 27.9%). And the tumor downstaging rate was also similar between the two groups (54.1vs. 59.1%). The compliance of chemotherapy was much better in concurrent chemoradiotherapy with mFOLFOX6 (93.5% vs. 39.5%). Higher incidence of grade 3/4neutropenia (16.1% vs. 30.1%, P < 0.01) was shown in concurrent chemoradiotherapy group than that of concurrent and consolidation chemoradiotherapy group.
Conclusions
Preoperative concurrent chemoradiotherapy with mFOLFOX6 showed similar efficacy with radiotherapy plus consolidation chemotherapy and higher compliance of chemotherapy. Long-term follow-up will assess whether the higher compliance would translates to better oncologic outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yanhong Deng.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract